Navigation Links
Topline Results from Phase 2 Clinical Trial of Oral NKTR-118 Presented at 20th American Academy of Pain Management Annual Clinical Meeting (AAPM) in Phoenix
Date:10/10/2009

PHOENIX and SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona. NKTR-118, an oral peripherally-acting opioid antagonist, is a late stage investigational product candidate in clinical development for the treatment of opioid-induced constipation. NKTR-118 was developed by Nektar, utilizing its proprietary small molecule advanced polymer conjugate technology platform.

Today's presentation at AAPM includes topline data previously announced by the company in March 2009. In a Phase 2 double-blind, randomized, placebo-controlled study of 208 patients with opioid-induced constipation, NKTR-118 met the primary endpoint of increase in spontaneous bowel movements over the baseline period. There was no reversal or reduction of opioid-mediated analgesia in any dose groups. NKTR-118 was also well tolerated with the most commonly reported side effects being dose-dependent gastrointestinal-related effects.

Download Today's Poster Presentation for NKTR-118

The poster presentation from today's AAPM 20th Annual Clinical Meeting can be found on Nektar's website at http://www.nektar.com/product_pipeline/cns_pain_oral_nktr-118and119.html

AAPM Poster #39: "NKTR-118 Significantly Reverses Opioid-Induced Constipation"

Complete Data from NKTR-118 Phase 2 Clinical Trial to be presented in Oral Plenary Session at ACG 2009

Data from the Phase 2 clinical trial of NKTR-118 have been accepted for presentation in an oral plenary session of the American College of Gastroenterology (ACG
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
2. HerbalScience Releases Results of Pilot Clinical Study on Efficacy of Its Proprietary Elderberry Extract in Addressing Flu-Like Symptoms
3. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
4. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
5. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
6. Biotel Announces Fourth Quarter and Year End Results
7. Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference
8. BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET
9. InteKrin Therapeutics Presents Positive INT131 Phase 2b Results at the 45th Annual European Association for the Study of Diabetes Meeting
10. Encouraging HIV/AIDS Vaccine Trial Results Support GeoVax Labs, Inc. Strategy
11. Sinobiopharma Reports Highlights From Audited Financial Results for the Fiscal Year Ended May 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 ... biopharmaceutical company advancing patient care in critical areas, announced ... shares of common stock, and warrants to purchase up ... an offering price of $4.00 per share and $.01 ... price of $5.00, are exercisable immediately, and expire 5 ...
(Date:12/24/2014)... 23, 2014 GMO corn cases filed ... Syngenta, are in the process of being consolidated in ... case is In Re: Syngenta AG MIR 162 Corn ... for the District of Kansas. , Management of the ... over to U.S. District Judge John W. Lungstrum.* , ...
(Date:12/24/2014)... 23, 2014 According to Ross Selinger, President ... of ITRA Global, the national office market continues to be ... This is evidenced by the third quarter’s surprising 3.9% GDP, ... Low energy costs have held inflation down and the Fed ... the housing market remaining soft. , This solid economic news ...
(Date:12/24/2014)... Diego, CA (PRWEB) December 23, 2014 ... where their Twitter followers can submit their #HolidayInTheLab ... themselves and their lab mates. , For those struggling ... lab mates, the Pipette.com Holiday in the Lab Contest ... Pipette.com Twitter followers to send pictures of ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2
... still have another two months of waiting for the new ... their eyes now on the first movie ever of carbon ... that graphene single-layered sheets of carbon atoms arranged like ... of the electronics industry, the audience for this new science ...
... Central Texas man receives groundbreaking therapy days after heart ... On March 30, the Heart Hospital of Austin ... a groundbreaking Phase II study designed to test the ... to repair damaged heart tissue after a heart attack. ...
... many more to attend global event for health care leaders ... Washington , D.C. ... Care Congress, April 14-16, Washington, D.C., is pleased to announce ... meet with top health leaders from the United States and ...
Cached Biology Technology:Spring 'blockbuster' movie now showing 2Spring 'blockbuster' movie now showing 3Spring 'blockbuster' movie now showing 4Spring 'blockbuster' movie now showing 5Heart Hospital of Austin First Site in World to Test Efficacy of New Adult Stem Cell Therapy to Treat Damaged Heart Tissue in Phase II Trial 2Health Care Innovations and Opportunities Attract Attendees from 40 Countries and Delegations from 12 to 6th Annual World Health Care Congress 2
(Date:12/10/2014)... 2014 CIE San Diego has launched an ... connective tissue that enhances care coordination among social service ... client-level information; earned a second $1 million grant from ... seniors aging in community and; will be recognized as ... th 4-6p. CIE San Diego today ...
(Date:12/5/2014)... VIEW, Calif. , Dec. 4, 2014 /PRNewswire/ ... safety has boosted investments in new testing and ... has also given rise to a range of ... by the requirements of Generation Y, which is ... technologies. As a result, product development strategies of ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin ... deployed, innovative test solutions for military, aerospace, and ... version of its successful TS-900 PXI semiconductor ... and features of high-end systems to customers at ... value compared to traditional ATE. ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... History Museum have again discovered infant dinosaur footprints in ... of Morrison. Dating from the Late Jurassic, some 148 ... Rocky Mountains rose, when Morrison was a broad savanna ... sauropods, according to discoverer Matthew Mossbrucker, the museum,s director. ...
... if you,re physically fit, you,re less likely to get a ... that some people are "naturally" in better shape than others, ... for disease risk and drug effectiveness in animal models. A ... of The FASEB Journal ( http://www.faseb.org ) started ...
... light on yeast and mammalian cells in her Duke University lab ... the result of a light-activated switch from a plant that has ... "on-off switch" to control cell growth or death, grow new tissue ... an assistant research professor in the biology department at Duke. ...
Cached Biology News:Morrison Natural History Museum discovers baby sauropod tracks 2Morrison Natural History Museum discovers baby sauropod tracks 3New strain of 'high-runner' rats uniquely resistant to disease -- all disease! 2Researchers could use plant's light switch to control cells 2
Reacts with methylated DNA from plants and vertebrates...
Mouse monoclonal [GB3] to Kalinin ( Abpromise for all tested applications). entrezGeneID: 3918 SwissProtID: Q13753...
Rabbit polyclonal to Tryptophanyl tRNA synthetase ( Abpromise for all tested applications). Antigen: Recombinant full length protein (Human): Tryptophanyl tRNA synthetase Entrez Gene ID: 745...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Biology Products: